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Glycoprotein IIb/IIIa Inhibition in the Setting of
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Montreal, Quebec, Canada
Glycoprotein (GP) IIb/IIIa inhibitors have been extensively studied in the setting of
percutaneous coronary intervention (PCI) and in the management of non–ST-segment
elevation acute coronary syndromes. However, the use of GP IIb/IIIa inhibitors is less well
established in the setting of acute ST-segment elevation myocardial infarction (MI). Multiple
nonrandomized studies suggest that combination therapy with GP IIb/IIIa inhibitors and
thrombolytic agents leads to increased rates of TIMI 3 flow. However, two clinical trials
involving over 22,000 patients demonstrated that combination therapy is associated with only
modest reductions in major adverse cardiac events, does not reduce mortality, and is
associated with an increase in bleeding. In the setting of primary PCI, four clinical trials
involving over 3,000 patients demonstrated that GP IIb/IIIa inhibition results in a significant
decrease in the need for urgent target vessel revascularization but not in reductions of death
or recurrent MI. Thus, GP IIb/IIIa inhibition may provide only limited benefits in the setting
of acute ST-segment elevation MI. (J Am Coll Cardiol 2003;42:1–6) © 2003 by the
American College of Cardiology Foundation
Three glycoprotein (GP) IIb/IIIa inhibitors are currently
available: abciximab (ReoPro), eptifibatide (Integrilin), and
tirofiban (Aggrastat). These agents have been extensively
studied in the setting of percutaneous coronary intervention
(PCI) and in the management of non–ST-segment eleva-
tion acute coronary syndromes. However, there have been
relatively few studies of these agents in the setting of acute
ST-segment elevation myocardial infarction (MI), and their
use in this setting is less well established. The purpose of
this paper is to examine the current literature on the efficacy
and safety of GP IIb/IIIa inhibition in the setting of acute
ST-segment elevation MI.
Several studies have examined whether GP IIb/IIIa
inhibitors alone can be used to improve Thrombolysis In
Myocardial Infarction (TIMI) flow in the setting of acute
ST-segment elevation MI (1–4). These studies demonstrate
that, in patients who receive GP IIb/IIIa inhibitors, up to
32% develop TIMI 3 flow by 90 min after administration.
In contrast, thrombolytic agents achieve TIMI 3 flow in up
to 57% of patients (1–3,5). Although thrombolytic agents
lead to higher rates of TIMI 3 flow, they paradoxically
increase platelet aggregation (6,7). Hence, the theoretical
foundation was laid for the use of combination therapy with
a thrombolytic agent plus a GP IIb/IIIa inhibitor. It was
hoped that this combination would increase reperfusion
rates, allow for reduced thrombolytic dosages, and decrease
bleeding complications.
COMBINATION THERAPY
Early studies suggested that combination therapy does, in
fact, lead to increased reperfusion rates over thrombolytics
alone. In the Integrelin to Manage Platelet Aggregation to
Combat Thrombosis in Acute Myocardial Infarction
(IMPACT-AMI) study, all patients received accelerated
alteplase (100 mg) with or without the addition of
eptifibatide and then underwent angiography at 90 min (8).
Rates of TIMI 3 flow improved with the addition of
eptifibatide (66% vs. 39%, p  0.006), and rates of TIMI 2
and 3 flow also improved (87% vs. 69%, p  0.01). The
TIMI 14 investigators reported similar results (5). They
found that the combination of tissue plasminogen activator
(50 mg) plus abciximab improved TIMI 3 flow at 60 min
(72% vs. 43%, p 0.0009). Results from other studies, such
as Integrelin and Reduced-dose Thrombolytics in Acute
Myocardial Infarction (INTRO AMI) and Strategies for
Patency Enhancement in the Emergency Department
(SPEED), also reported higher rates of TIMI 3 flow in
patients receiving combination therapy (3,4) (Fig. 1).
Only two randomized trials have examined the impact of
combination therapy on clinical events (Table 1). The
Global Utilization of Strategies to open Occluded Coronary
Arteries-V (GUSTO-V) trial compared thrombolytic ther-
apy alone versus the combination of abciximab plus throm-
bolytic therapy in the setting of acute ST-segment elevation
MI (9). A total of 16,588 patients were randomized within
6 h of the onset of chest pain to full dose reteplase or to half
dose reteplase plus full dose abciximab. Patients in both
arms of the trial received unfractionated heparin. The
primary end point was mortality. At 30 days, the investiga-
tors found no difference between the two treatment arms in
terms of the primary end point (reteplase 5.9% vs. combi-
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nation 5.6%, p  0.43). Similarly, no significant difference
was seen in the occurrence of stroke (0.3% vs. 0.2%,
respectively, p 0.37). In addition, none of the prespecified
subgroups (e.g., women, elderly, diabetics, anterior MI)
appeared to have a clinical benefit with combination therapy
in terms of mortality. However, the investigators did ob-
serve that combination therapy was associated with modest
reductions in the rates of certain prespecified complications
such as reinfarction (3.5% vs. 2.3%, p 0.0001), ventricular
fibrillation (3.5% vs. 2.7%, p  0.01), and ventricular septal
defect (0.3% vs. 0.2%, p  0.05).
Although combination therapy was associated with mod-
est reductions in some clinical events, rates of bleeding and
need for transfusion were significantly higher with combi-
nation therapy. Severe bleeding occurred in 0.5% of patients
receiving thrombolytic therapy alone versus 1.1% of patients
receiving combination therapy (p  0.0001). Transfusions
were required in 4.0% of patients who received thrombolytic
therapy alone versus 5.7% of patients who received combi-
nation therapy (p  0.0001). Mild to severe bleeding
occurred in 13.7% of patients who received thrombolytic
therapy alone versus almost 25% of patients who received
combination therapy (p  0.0001). Importantly, among
patients 75 years of age, intracranial hemorrhage occurred
less frequently with thrombolytic therapy than with combi-
nation therapy (1.1% vs. 2.1%, p  0.069) (9).
The GUSTO-V investigators recently published their
one-year follow-up results (10). Similar to their mortality
results at 30 days, no mortality benefit was seen at one year
for patients treated with reteplase alone versus combination
therapy (8.4% vs. 8.4%, respectively, p  0.99) (10). Thus,
the GUSTO-V trial demonstrated that combination ther-
apy with half-dose reteplase plus full-dose abciximab leads
to only modest clinical benefits but at the cost of increased
bleeding complications.
Abbreviations and Acronyms
ADMIRAL  Abciximab Before Direct Angioplasty
and Stenting in MI Regarding Acute
and Long-term Follow-up
ASSENT-III  Assessment of the Safety and Efficacy
of a New Thrombolytic-III
CADILLAC  Controlled Abciximab and Device
Investigation to Lower Late
Angioplasty Complications
GP  glycoprotein
GUSTO-V  Global Utilization of Strategies to
open Occluded Coronary Arteries-V
IMPACT-AMI  Integrelin to Manage Platelet
Aggregation to Combat Thrombosis
in Acute Myocardial Infarction
INTRO AMI  Integrelin and Reduced-dose
Thrombolytics in Acute Myocardial
Infarction
ISAR-2  Intracoronary Stenting and
Antithrombotic Regimen-2
MI  myocardial infarction
PCI  percutaneous coronary intervention
RAPPORT  Reopro in Acute Myocardial
Infarction and Primary PTCA
Organization and Randomized Trial
SPEED  Strategies for Patency Enhancement
in the Emergency Department
TIMI  Thrombolysis In Myocardial
Infarction
Figure 1. Percentage of patients with acute myocardial infarction achieving Thrombolysis In Myocardial Infarction (TIMI) 3 flow at 90 min after use of
thrombolytic therapy alone versus thrombolytic therapy plus a glycoprotein (GP) IIb/IIIa inhibitor. Data adapted from references 3 to 5 and 8. For
abbreviations see Abbreviations box.
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The Assessment of the Safety and Efficacy of a New
Thrombolytic-III (ASSENT-III) trial also examined the
use of combination therapy in the setting of acute ST-
segment elevation MI (11). A total of 6,095 patients were
randomized in this trial 6 h from the onset of chest pain.
Patients were randomized to one of three arms: 1) full dose
tenecteplase-tissue plasminogen activator plus standard dose
unfractionated heparin, 2) full dose tenecteplase-tissue plas-
minogen activator plus low-molecular-weight heparin
(enoxaparin), and 3) half dose tenecteplase-tissue plasmin-
ogen activator plus full dose abciximab. The primary out-
come was a composite of death, reinfarction, and refractory
ischemia. The investigators found that patients who re-
ceived unfractionated heparin had significantly higher rates
of the primary end point than those who received enoxapa-
rin or abciximab (15.4% vs. 11.4% and 11.1%, respectively,
p  0.0001 for unfractionated heparin vs. pooled). For the
secondary composite end point, which was composed of the
primary end point plus intracranial hemorrhage and major
bleeding, the enoxaparin group (13.8%) fared slightly better
than the abciximab group (14.2%) while the unfractionated
heparin group (17.0%) was inferior (p  0.008 for unfrac-
tionated heparin versus pooled) (2). Major bleeding events
were seen most commonly in the abciximab group (4.3%),
then in the enoxaparin group (3.0%), and lastly in the
heparin group (2.2%) (p 0.0005 for abciximab vs. pooled).
Patients in each of the three groups had an intracranial
hemorrhage rate of 0.9%. Thus, while combination therapy
was more efficacious than tenecteplase-tissue plasminogen
activator plus unfractionated heparin, tenecteplase-tissue
plasminogen activator plus enoxaparin was associated with
clinical benefits similar to those with combination therapy
but with lower rates of bleeding.
Thus, both the GUSTO-V and ASSENT-III trials
showed comparable results. Combination therapy consisting
of a half dose thrombolytic agent plus full dose abciximab
was not found to be superior to full dose thrombolytic
therapy. Although both trials suggested a modest clinical
benefit with combination therapy, bleeding complications
were increased. In addition, ASSENT-III suggested that
thrombolytic therapy plus low-molecular-weight heparin
provided similar clinical outcomes as combination therapy
but without the higher bleeding complications.
PRIMARY PCI
Primary PCI has been found to be superior to thrombolytic
therapy in multiple randomized trials (12–15). Because of
the increasing use of primary PCI, investigation into the
utility of GP IIb/IIIa inhibition in this setting is germane
(16). Four clinical trials have examined the use of GP IIb/
IIIa inhibition in the setting of primary PCI (Table 2). The
Reopro in Acute Myocardial Infarction and Primary PTCA
Organization and Randomized (RAPPORT) trial com-
pared GP IIb/IIIa inhibition versus placebo in the setting of
primary PCI (17). A total of 482 patients underwent
primary PCI within 12 h of chest pain onset. Patients
received either abciximab as an intravenous bolus followed
by a 12-h infusion or placebo bolus and infusion. The
primary end point of death, recurrent MI, and target vessel
revascularization was significantly reduced by abciximab at
both 30 days (5.8% vs. 11.2%, p  0.03) and 6 months
(11.6% vs. 17.8%, p  0.05). However, there was no
difference in the composite of death or MI at 30 days (4.6%
vs. 5.8%, p 0.52) or 6 months (8.7% vs. 11.2%, p 0.36).
Thus, the reduction in the primary end point was driven by
the reduction in the need for urgent target vessel revascu-
larization at 30 days (1.7% vs. 6.6%, p  0.006) and at 6
months (3.3% vs. 8.7%, p  0.01).
The Intracoronary Stenting and Antithrombotic
Regimen-2 (ISAR-2) trial compared abciximab plus hepa-
rin versus heparin alone on restenosis after primary stent
implantation in the setting of acute MI (18). This study was
a single blind trial involving 401 patients with ST-segment
elevation MI who underwent cardiac catheterization and
stent implantation within 48 h of the onset of chest pain.
Table 1. Rates of Clinical Events at 30 Days in Patients Undergoing Thrombolytic Versus Combination Therapy in the Setting of
Acute MI
No. (%) Death
Recurrent
MI Ischemia
Major
Bleeding
Complications Composite
GUSTO-V (n  16,588)
Half-dose reteplase  abciximab (n  8,328) 468 (5.6) 191 (2.3)* 941 (11.3) 90 (1.1) NR
Full-dose reteplase (n  8,260) 488 (5.9) 289 (3.5) 1,057 (12.8) 42 (0.5)* NR
ASSENT-III (n  6,095)
Half-dose tenecteplase-tissue plasmininogen
activator  abciximab (n  2,017)
133 (6.6) 44 (2.2)† 64 (3.2)† 62 (4.3) 223 (11.1)†
Full-dose tenecteplase-tissue plasmininogen
activator  enoxaparin (n  2,040)
109 (5.4) 54 (2.7)† 93 (4.6)† 87 (3.0)‡ 233 (11.4)†
Full-dose tenecteplase-tissue plasmininogen
activator  unfractionated heparin (n  2,038)
122 (6.0) 86 (4.2) 132 (6.5) 44 (2.2)‡ 314 (15.4)
*p  0.05; †the abciximab arm was statistically different from the unfractionated heparin arm, and the enoxaparin arm was statistically different from the unfractionated heparin
arm, but there was no difference between the abciximab and enoxparin arms; ‡the abciximab arm was statistically different from the unfractionated heparin arm, but there was
no difference between the enoxaparin and unfractionated heparin arms. Adapted from references 9–11.
ASSENT-III  Assessment of the Safety and Efficacy of a New Thrombolytic; GUSTO-V  Global Utilization of Strategies to open Occluded Coronary Arteries-V; MI
 myocardial infarction; NR  not reported.
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For the primary end point of restenosis, the ISAR-2
investigators found that there was no impact with GP IIb/
IIIa inhibition. However, the investigators also reported on
clinical event rates at both 30 days and 6 months. They
found that the composite end point of death, recurrent MI,
and ischemic target lesion revascularization was reduced in
the heparin plus abciximab group at 30 days (5.0% vs.
10.5%, p  0.038). There was also a nonsignificant reduc-
tion in the secondary composite end point of death or
recurrent MI (2.5% vs. 6.0%, p  0.08). At six months,
however, a significant reduction in the composite end point
was no longer present (p 0.17). Thus, in the ISAR-2 trial,
abciximab exerted beneficial effects at 30 days by reducing
the rate of major cardiac events (primarily ischemic target
lesion revascularization), but this finding was no longer
present at 6 months.
The Abciximab Before Direct Angioplasty and Stenting
in MI Regarding Acute and Long-term Follow-up
(ADMIRAL) trial was the first to examine the use of
GP IIb/IIIa inhibition using contemporary primary PCI
techniques (19). The purpose of this trial was to compare
primary PCI with stenting plus abciximab versus primary
PCI with stenting alone. The trial enrolled 300 patients
with ST-segment elevation MI randomized within 12 h of
the onset of chest pain. Patients received either abciximab or
placebo before arterial sheath insertion and cardiac cathe-
terization. The investigators found a significant reduction in
the composite outcome of death, recurrent MI, and urgent
target vessel revascularization at both 30 days (abciximab
6.0% vs. placebo 14.6%, p  0.01) and 6 months (7.4% vs.
15.9%, p  0.02). As in the RAPPORT trial, however, the
reduction in the primary end point was solely driven by the
reduction in urgent target vessel revascularization. There
was a significant reduction in urgent target vessel revascu-
larization at 30 days (1.3% vs. 6.6%, p  0.02) and at 6
months (2.0% vs. 6.6%, p  0.049), while there was no
reduction in death or recurrent MI.
The Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications (CADILLAC)
trial examined the interaction between stenting and
GP IIb/IIIa inhibition in the setting of primary PCI (20). A
total of 2,082 patients were randomized in a two-by-two
factorial design to one of four arms: balloon angioplasty
alone (n  518), balloon angioplasty plus abciximab (n 
528), stenting alone (n  512), and stenting plus abciximab
(n  524). In comparison with the ADMIRAL trial,
abciximab was given only at the time of angioplasty. The
investigators found that rates of TIMI 3 flow were similar in
each of the four arms of the trial after PCI and that there
were no differences in either death or recurrent MI. There
was a substantial reduction in ischemic target vessel revas-
cularization with the use of stenting and a further modest
reduction with the addition of abciximab. At six months,
patients who received stenting plus abciximab had an
ischemic target vessel revascularization rate of 5.2% versus
8.3% in patients who received stenting alone (p 0.47). ForTa
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the composite of major adverse cardiac events, there was a
substantial reduction for patients who received stents. How-
ever, the addition of abciximab did not appear to provide
additional clinical benefit. Thus, routine stent implantation
during primary PCI resulted in lower rates of clinical events
when compared with balloon angioplasty alone. The use of
abciximab reduced the rates of ischemic target vessel revas-
cularization after both balloon angioplasty and stenting.
Abciximab did not, however, significantly improve TIMI
flow rates after either balloon angioplasty or stenting. The
relative lack of benefit of abciximab in the CADILLAC
trial may have been due to its later administration compared
with its early administration in the ADMIRAL trial.
It is important to note that abciximab is not the only GP
IIb/IIIa inhibitor that has been examined in the setting of
primary PCI. The Emergency Room Administration of
Eptifibatide before Primary Angioplasty (RAPIER) study
involved the use of eptifibatide in patients with acute
ST-segment elevation MI (21). Patients in the early treat-
ment arm received administration of epitfibatide in the
emergency room, and another dose on arrival in the cathe-
terization laboratory. Patients in the late treatment arm only
received eptifibatide in the catheterization laboratory. The
TIMI 2 and 3 flow rates at the time of angiography were
higher in the early treatment arm (56.7% vs. 13.3%, respec-
tively, p  0.001). Unfortunately, the RAPIER study was
not a randomized trial, and the study was underpowered to
examine clinical events.
POOLED ANALYSIS
We pooled the results of the four trials examining the use of
abciximab in the setting of primary PCI (Table 3). We
divided the trials into those that examined balloon angio-
plasty alone and those that examined angioplasty plus
stenting. It is important to note that, in the balloon
angioplasty trials, stents were used as a bail-out treat-
ment, and, consequently, only 14.5% of patients in the
RAPPORT trial and 16.0% of patients in the balloon
angioplasty arm of the CADILLAC trial received stents. Of
the patients enrolled in the stent trials, 99.0% in ISAR-2,
92.0% in ADMIRAL, and 98.0% in the stent arm of
CADILLAC received at least one stent (17–20).
At 30 days, the use of abciximab resulted in significant
reductions in the composite end point of death, recurrent
MI, and urgent target vessel revascularization in both the
balloon angioplasty and stent groups. The reduction in the
composite end point was driven by substantial reductions in
rates of urgent target vessel revascularization, and there was
no major difference between the angioplasty and stent
groups. At six months, results were similar. Abciximab use
was associated with a 27% reduction in composite events,
but this outcome was solely driven by the reduction in
urgent target vessel revascularization. From our pooled
results, it is apparent that abciximab use in the setting of
primary PCI is associated with a substantial reduction in
urgent target vessel revascularization at 30 days, and this
result still persists at 6 months. We further calculated that
37 patients need to be treated with a GP IIb/IIIa inhibitor
in order to prevent one urgent target vessel revascularization
at 30 days, and 33 patients need to be treated to prevent one
urgent target vessel revascularization at six months.
CONCLUSIONS
Although GP IIb/IIIa inhibitors have been closely studied
in the setting of both PCI and non–ST-segment elevation
acute coronary syndromes, relatively few studies have exam-
ined their use in the setting of acute ST-segment elevation
MI. Because GP IIb/IIIa inhibitors are potent suppressors
of platelet aggregation and because acute MI is due to
platelet-dependent thrombus formation, there is a good
theoretical foundation for the use of GP IIb/IIIa inhibitors
in this setting. However, clinical trials examining the
combination of GP IIb/IIIa inhibitors with thrombolytic
agents have been disappointing. Combination therapy has
not been found to reduce mortality, is only associated with
modest reductions in some clinical events, and has been
Table 3. Pooled Results of the RAPPORT, ISAR-2, ADMIRAL, and CADILLAC Trials
Death Recurrent MI
Urgent Target
Vessel
Revascularization*
Total Target
Vessel
Revascularization† Composite
30 Days (odds ratio [95% CI])
PTCA trials (n  1,529) 0.65 (0.31–1.37) 0.84 (0.39–1.84) 0.47 (0.28–0.79) 0.64 (0.43–0.96) 0.53 (0.35–0.79)
Stent trials (n  1,737) 0.91 (0.54–1.54) 0.57 (0.22–1.46) 0.38 (0.18–0.79) 0.68 (0.40–1.14) 0.56 (0.37–0.85)
Pooled (n  3,266) 0.71 (0.46–1.11) 0.71 (0.40–1.30) 0.43 (0.28–0.66) 0.66 (0.48–0.91) 0.54 (0.41–0.71)
6 Months (odds ratio [95% CI])
PTCA trials (n  1,529) 0.66 (0.38–1.13) 1.10 (0.65–1.87) 0.76 (0.56–1.04) 0.93 (0.71–1.21) 0.73 (0.56–0.96)
Stent trials‡ (n  1,336) 1.02 (0.59–1.77) 1.06 (0.51–2.21) 0.55 (0.35–0.87) 0.72 (0.53–0.97) 0.71 (0.53–0.96)§
Pooled (n  2,865) 0.82 (0.56–1.20) 1.09 (0.71–1.67) 0.69 (0.53–0.89) 0.83 (0.68–1.01) 0.73 (0.60–0.88)
PTCA (balloon angioplasty) trials  RAPPORT, 2 arms of CADILLAC; stent trials  ISAR-2, ADMIRAL, 2 arms of CADILLAC. *Urgent target vessel revascularization
rates are not reported for ISAR-2; †Total target lesion revascularization rates were reported for ISAR-2; ‡ISAR-2 did not report 6-month rates of death, recurrent MI, and total
target lesion revascularization. They did, however, present an event-free survival curve, from which the composite rate of death/MI/total target lesion revascularization was
extrapolated; §n  1,737 (to include ISAR-2; n  3,266 (to include ISAR-2). 30-day and 6-month data from each trial comparing abciximab with placebo were pooled by
weighting the results in proportion to sample size. Data taken from references 17–20.
CI  confidence interval; MI  myocardial infarction; PTCA  percutaneous coronary intervention. Other abbreviations as in Abbreviations box.
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associated with increased rates of bleeding. In the setting of
primary PCI, results have been somewhat more promising.
The use of GP IIb/IIIa inhibitors in this setting leads to
substantial reductions in rates of urgent target vessel revas-
cularization. However, reductions in death and recurrent
MI have not been demonstrated.
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